CN104523717A - Simethicone otilonium bromide chewable tablets and preparing method thereof - Google Patents
Simethicone otilonium bromide chewable tablets and preparing method thereof Download PDFInfo
- Publication number
- CN104523717A CN104523717A CN201510004527.6A CN201510004527A CN104523717A CN 104523717 A CN104523717 A CN 104523717A CN 201510004527 A CN201510004527 A CN 201510004527A CN 104523717 A CN104523717 A CN 104523717A
- Authority
- CN
- China
- Prior art keywords
- simethicone
- otilonium bromide
- chewable tablet
- parts
- bromide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses simethicone otilonium bromide chewable tablets and a preparing method of the simethicone otilonium bromide chewable tablets. The simethicone otilonium bromide chewable tablets comprise, by mass, 12.5 parts of simethicone, 4 parts of otilonium bromide, 10-40 parts of adsorbent, 25-75 parts of filler, 0.2-10 parts of adhesive, 0.2-5.0 parts of lubricant, 0.5-10 parts of corrigent, 0.05-0.5 part of aromatic and 1.5-7.5 parts of moisture sealer coating materials. According to the simethicone otilonium bromide chewable tablets, the formula is reasonable, the cost is low, and the preparing method is simple and suitable for industrial production. The prepared tablets are good in taste, the surfaces of the tablets are smooth and attractive, the tablets are even in color, appropriate in hardness, stable in quality, convenient to take and carry, and particularly suitable for the elderly, children and patients who cannot swallow solid preparations, the compliance of the patients is improved, and the simethicone otilonium bromide chewable tablets have good application prospects to treatment of the irritable bowel syndrome due to various reasons, especially the irritable bowel syndrome accompanied with abdominal distension and stomachache.
Description
Technical field
The invention belongs to pharmaceutical field, be specifically related to Simethicone otilonium Bromide chewable tablet, also relate to the preparation method of this chewable tablet.
Background technology
Gastrointestinal dysfunction (WSN) is the general name of one group of gastrointestinal syndrome.The digestive tract such as epigastric discomfort, anorexia, abdominal distention, stomachache, diarrhoea, belch, acid regurgitation, Nausea and vomiting, constipation is not only had to show clinically, also the normal neurosis with general shows, as insomnia, dreaminess, forgetful, physical tiredness, absent minded, cardiopalmus, uncomfortable in chest, headache, dizziness, spontaneous perspiration, night sweat etc., be clinical common chronic, stubborn disease.The generation of WSN is normal relevant with Nervous and Mental Factors, disorder of emotion, ponders over the tired generation causing WSN of labor.The distinguishing feature of WSN is the clinical manifestation having a series of WSN, but without organic disease in pathology, dissection etc.Therefore, modern medicine cannot make a definite diagnosis WSN, and the medicine that also inefficacy is definite can only make anti symptom treatment or auxiliary therapy.In fact, flatulence and digestive tract pain are also the common manifestations of WSN.Flatulence is that cause of disease effect gastrointestinal makes gas produce the abdominal distension too much caused, and digestive tract pain is then the abdominal pain that cause of disease effect gastrointestinal smooth muscle makes its excess shrinkage or strong contraction cause.Although the life of WSN to people endangers without lethal, also can not affect the life-span of people, quality of life can be caused to decline, affect people and live normally, work.
Irritable bowel syndrome (irritable bowel syndrome, IBS), be a kind of syndrome in modal gastrointestinal dysfunction (WSN), after, feces character exception frequent with chronic or RAP, abdominal distention companion defecation/awareness of defecation and defecation, symptom is improved as cardinal symptom.The pathogenesis of IBS is not yet clear and definite at present, may be relevant with many factors such as psychologic factors, visceral hypersensitivity, gastrointestinal tract dynamia exception, dysimmunity, infection, but large quantity research shows that digestive tract power may be the main cause of the generation of IBS extremely, special relevant with spasmodic contraction frequent activity.Therefore, improve the important means that digestive tract power is Current therapeutic IBS extremely, at present for the medicine of gastrointestinal motility abnormal (the caused stomachache of gastrointestinal smooth muscle excess shrinkage), mainly contain mebeverine, pinaverium bromide, trimebutine, otilonium Bromide etc., the curative effect alleviating stomachache is better, but to IBS with abdominal distention nearly unavailable.
Simethicone is the complex of polydimethylsiloxane and silicon dioxide composition, it is a kind of stable nonionic surfactant, mainly act in digestive tract the bubble surface be present in chyme and mucus, reduce bubble surface tension force, bubbles burst is impelled to discharge gas, the gas disengaged can part be absorbed by intestinal wall, and also can discharge with intestinal peristalsis promoting, thus Simethicone has froth breaking, relieving distension effect.Simethicone belongs to pharmacology and physiology's inert substance, and froth breaking act as pure physical property effect, does not relate to chemical reaction.After Simethicone oral administration, discharge with prototype again after gastrointestinal transit, and the sub-acute toxicity test of rat shows that Simethicone does not have toxic action, not yet observes the untoward reaction relevant with taking Simethicone so far.Simethicone, based on its good safety, can be widely used in infant, child, adult, anemia of pregnant woman, patient with operation, gerontal patient etc.; Based on the defoaming that it is good, be mainly used in the adjuvant drug etc. of the abdominal distention, abdominal discomfort, dyspepsia, postoperative ileus and the abdominal part imaging examination that cause because of air accumulation abdominal part clinically.
Otilonium Bromide, chemistry N, N-diethyl-N-methyl-2-by name [[4 [[2-(octyl group) benzoyl] is amino] benzoyl] oxygen base] ethane ammonium bromide, being a kind of cholinergic receptor antagonist, is also a kind of calcium antagonist.The otilonium Bromide entering gastrointestinal can suppress Ca
2+by L-type Ca
2+passage enters intestinal smooth muscle cells, thus reduces the contractility of intestinal smooth muscle cells.On pharmacotherapeutics, otilonium Bromide belongs to cholinolytic class spasmolytic, for gastrointestinal smooth muscle, there is the effect of selectivity solution spasm, be therefore applicable to all gastrointestinal motility hyperfunctioning, different reason and different parts and the spasm reaction caused due to smooth muscle pathologic atrophy.In addition, results of animal shows, otilonium Bromide non-toxic reaction, concerning the problem that may occur hardly the mankind because overdose causes.So, otilonium Bromide is widely used as a kind of spasmolytic, effectively and safety, clinically for stomachache, irritable bowel syndrome, gastritis, duodenitis, enteritis, esophageal lesion etc. that cramps of gastrointestinal tract and gastrointestinal motility disorders cause, also before can be used for splanchnoscopy, medication is (as esophageal-gastric-duodenoscope, colonoscope, rectoscope etc.).
But up to now, be showed no Simethicone and otilonium Bromide both at home and abroad and combine the research being prepared into chewable tablet and report, also go on the market without Related product.Therefore, develop Simethicone otilonium Bromide chewable tablet and there is good market prospect.
Summary of the invention
In view of this, an object of the present invention is to provide Simethicone otilonium Bromide chewable tablet, and formula is reasonable, with low cost; Two of object of the present invention is the preparation method providing Simethicone otilonium Bromide chewable tablet, and preparation method is simple, is convenient to suitability for industrialized production.
For solving foregoing invention object, the invention provides following technical scheme:
1, Simethicone otilonium Bromide chewable tablet, composed of the following components by mass parts: Simethicone 12.5 parts, otilonium Bromide 4 parts, adsorbent 10-40 part, filler 25-75 part, adhesive 0.2-10 part, lubricant 0.2-5.0 part, correctives 0.5-10 part, aromatic 0.05-0.5 part and damp-proof membrane coating materials 1.5-7.5 part.
Preferably, composed of the following components by mass parts: Simethicone 12.5 parts, otilonium Bromide 4 parts, adsorbent 16-32 part, filler 42-57.64 part, adhesive 2-2.6 part, lubricant 0.5-0.6 part, correctives 5.2-5.5 part, aromatic 0.14-0.15 part and damp-proof membrane coating materials 3.3-3.6 part.
Preferably, described adsorbent is one or more in corn starch, microcrystalline Cellulose, dextrin, calcium hydrogen phosphate.
Preferably, described filler is one or more in corn starch, sucrose, microcrystalline Cellulose, pregelatinized Starch, glucose, lactose, mannitol, xylitol, maltose alcohol.
Preferably, described lubricant is one or more in magnesium stearate, Pulvis Talci, micropowder silica gel.
Preferably, described adhesive is one or more in PVP-K30, starch slurry, low substituted hydroxy-propyl fiber.
Prepare chewable tablet in the present invention, compared with conventional tablet, its mouthfeel wants better.Therefore, in formula, add suitable correctives to improve mouthfeel, improve the drug compliance of patient.In the present invention, correctives is preferably one or more in aspartame, steviosin, saccharin sodium, vanillin, adds the pleasantly sweet filler of band simultaneously and improves mouthfeel better, patient is taken like a shot.In addition, for the object improving chewable tablet fragrance, in prescription of the present invention, pharmaceutically acceptable essence is added.
In prescription of the present invention, otilonium Bromide meets water unstable at ambient temperature, and facile hydrolysis generates 4-(2-octyloxy benzamido) benzoic acid and N-methyl-N, N-diethyl-N-(2-ethoxy) ammonium bromide.In order to ensure the impact of chewable tablet not by the moisture absorption in storage process, improving the stability of tablet, extending shelf life, the chewable tablet label of the present invention to compacting carries out moisture-proof film coating.Preferred moisture-proof film coating materials is hydroxypropyl emthylcellulose, methylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose.
2, the preparation method of described Simethicone otilonium Bromide chewable tablet, comprises the following steps:
A. pulverize: the solids fraction in prescription is ground into the fine powder that granularity is more than 80 orders respectively;
B. granulate: the Simethicone getting formula ratio is mixed homogeneously with adsorbent, add filler, otilonium Bromide and correctives mix homogeneously again, add adhesive after mixing and make soft material, soft material is crossed 20 mesh sieves and granulate, then dry at 40 ~ 60 DEG C, finally cross 20 mesh sieve granulate;
C. tabletting: aromatic is evenly sprayed into mix homogeneously in the dry granule of step b granulate, then add the lubricant of recipe quantity, mixing, tabletting, obtains Simethicone otilonium Bromide chewable tablet label;
D. coating: moisture-proof film coating materials dissolve with ethanol is made the solution that mass fraction is 6-18%, carries out coating to step c gained Simethicone otilonium Bromide chewable tablet label, dry, i.e. obtained Simethicone otilonium Bromide chewable tablet.
In prescription of the present invention, Simethicone is the oily liquids of thickness, and poor fluidity should not use direct powder compression tabletting.Therefore the present invention selects wet granule compression tablet legal system for chewable tablet.When granulating, the present invention first selects common oily Drug absorbability filler (as microcrystalline Cellulose, starch, dextrin etc.) to adsorb Simethicone, so that it is uniformly dispersed, and then granulate after mixing homogeneously with otilonium Bromide, filler and other solid adjuvant materials.
Beneficial effect of the present invention is: the invention provides a kind of Simethicone otilonium Bromide chewable tablet, select pharmaceutically acceptable adjuvant and screen adjuvant component and proportioning thereof and optimize, Formulation is reasonable; Simultaneously, the preparation method of the present invention to Simethicone otilonium Bromide chewable tablet also designs and optimizes, easy and simple to handle, with low cost, be applicable to suitability for industrialized production, gained tablet is stable and controllable for quality, good mouthfeel, smooth surface is attractive in appearance, uniform color, and hardness is moderate, in treatment because the irritable bowel syndrome caused by a variety of causes has a good application prospect with in abdominal distention, stomachache especially.
Detailed description of the invention
Below in conjunction with preferred embodiment, the present invention is described in detail.The experimental technique of unreceipted actual conditions in embodiment, the usually conveniently conditioned disjunction condition of advising according to manufacturer.
Embodiment 1
Simethicone otilonium Bromide chewable tablet, concrete formula is as follows:
Above-mentioned formula is made 1000 Simethicone otilonium Bromide chewable tablet, preparation method comprises the steps:
A. the solids fraction (otilonium Bromide, corn starch, glucose, magnesium stearate, saccharin sodium) in formula is ground into the fine powder that granularity is more than 80 orders respectively; The PVP-K30 of formula ratio is mixed with PVP-K30 ethanol (50%) solution of 10%;
B. the Simethicone getting formula ratio is mixed homogeneously with corn starch; Mix homogeneously with the otilonium Bromide of formula ratio, glucose, saccharin sodium again; Add 10%PVP-K30 alcoholic solution and make soft material, cross 20 mesh sieves and granulate, 40 DEG C of dryings, then cross 20 mesh sieve granulate;
C. the essence of formula ratio is evenly sprayed on the dry particle surface after step b granulate, seals a moment, then add the magnesium stearate of formula ratio with sealing bag, mixing, tabletting, obtains Simethicone otilonium Bromide chewable tablet label;
D. moisture-proof film coating materials hydroxypropyl emthylcellulose dissolve with ethanol is made the solution that mass fraction is 13%, then to Simethicone otilonium Bromide chewable tablet label coating, dry, i.e. obtained Simethicone otilonium Bromide chewable tablet.
Quality examination:
Simethicone otilonium Bromide chewable tablet any surface finish, uniform color that the present embodiment is obtained; Good mouthfeel, savory; Hardness is 6.5 ~ 7.5kg; Dissolution test: when 30 minutes, the dissolution of Simethicone is 77.2%, and the dissolution of otilonium Bromide is 79.5%.
Embodiment 2
Simethicone otilonium Bromide chewable tablet, concrete formula is as follows:
Above-mentioned formula is made 1000 Simethicone otilonium Bromide chewable tablet, preparation method comprises the steps:
A. the solids fraction (otilonium Bromide, corn starch, sucrose, mannitol, magnesium stearate, aspartame) in formula is ground into the fine powder that granularity is more than 80 orders respectively; The PVP-K30 of formula ratio is mixed with PVP-K30 ethanol (50%) solution of 10%;
B. the Simethicone getting formula ratio is mixed homogeneously with corn starch; Mix homogeneously with the otilonium Bromide of formula ratio, mannitol, sucrose, aspartame again; Add 10%PVP-K30 alcoholic solution and make soft material, cross 20 mesh sieves and granulate, 40 DEG C of dryings, then cross 20 mesh sieve granulate;
C. the essence of recipe quantity is evenly sprayed on the dry particle surface that step b arranges, seals a moment, then add the magnesium stearate of formula ratio with sealing bag, mixing, tabletting, obtains Simethicone otilonium Bromide chewable tablet label;
D. moisture-proof film coating materials hydroxypropyl emthylcellulose dissolve with ethanol is made the solution that mass fraction is 13%, then to Simethicone otilonium Bromide chewable tablet label coating, dry, i.e. obtained Simethicone otilonium Bromide chewable tablet.
Quality examination: Simethicone otilonium Bromide chewable tablet any surface finish, uniform color that the present embodiment is obtained; Good mouthfeel, savory; Hardness is 6.0-8.0kg; Dissolution test: when 30 minutes, the dissolution of Simethicone is 76.7%, and the dissolution of otilonium Bromide is 78.6%.
Embodiment 3
Simethicone otilonium Bromide chewable tablet, concrete formula is as follows:
Above-mentioned formula is made 1000 Simethicone otilonium Bromide chewable tablet, preparation method comprises the steps:
A. the solids fraction (otilonium Bromide, microcrystalline Cellulose, mannitol, magnesium stearate, micropowder silica gel, saccharin sodium) in formula is ground into the fine powder that fineness is more than 80 orders respectively; The PVP-K30 of formula ratio is mixed with PVP-K30 ethanol (50%) solution of 10%;
B. the Simethicone getting formula ratio is mixed homogeneously with microcrystalline Cellulose; Mix homogeneously with recipe quantity otilonium Bromide, mannitol, saccharin sodium again; Add 10%PVP-K30 alcoholic solution and make soft material, cross 20 mesh sieves and granulate, 50 DEG C of dryings, then cross 20 mesh sieve granulate;
C. the essence of formula ratio is evenly sprayed on the dry particle surface of step b granulate, seals a moment, then add magnesium stearate, the micropowder silica gel of formula ratio with sealing bag, mixing, tabletting, obtains Simethicone otilonium Bromide chewable tablet label;
D. moisture-proof film coating materials methylcellulose dissolve with ethanol is made the solution that mass fraction is 13%, then coating is carried out to Simethicone otilonium Bromide chewable tablet label, dry, i.e. obtained Simethicone otilonium Bromide chewable tablet.
Quality examination: Simethicone otilonium Bromide chewable tablet any surface finish, uniform color that the present embodiment is obtained; Good mouthfeel, savory; Hardness is 6.3-7.8kg; Dissolution test: when 30 minutes, the dissolution of Simethicone is 76.9%, and the dissolution of otilonium Bromide is 80.0%.
Embodiment 4
Simethicone otilonium Bromide chewable tablet, concrete formula is as follows:
Above-mentioned formula is made 1000 Simethicone otilonium Bromide chewable tablet, preparation method comprises the steps:
A. the solids fraction (otilonium Bromide, calcium hydrogen phosphate, corn starch, glucose, magnesium stearate, aspartame) in formula is ground into the fine powder that fineness is more than 80 orders respectively;
B. the Simethicone getting formula ratio is mixed homogeneously with calcium hydrogen phosphate; Mix homogeneously with the otilonium Bromide of formula ratio, corn starch, glucose, aspartame again; Add 10% starch slurry and make soft material, cross 20 mesh sieves and granulate, 40 DEG C of dryings, then cross 20 mesh sieve granulate;
C. the essence of formula ratio is evenly sprayed on the dry particle surface of step b granulate, seals a moment, then add the magnesium stearate of formula ratio with sealing bag, mixing, tabletting, obtains Simethicone otilonium Bromide chewable tablet label;
D. moisture-proof film coating materials hydroxypropyl emthylcellulose dissolve with ethanol is made the solution that mass fraction is 13%, then to Simethicone otilonium Bromide chewable tablet label coating, dry, i.e. obtained Simethicone otilonium Bromide chewable tablet.
Quality examination: Simethicone otilonium Bromide chewable tablet any surface finish, uniform color that the present embodiment is obtained; Good mouthfeel, savory; Hardness is 6.5-8.0kg; Dissolution test: when 30 minutes, the dissolution of Simethicone is 77.4%, and the dissolution of otilonium Bromide is 79.8%.
Embodiment 5
Simethicone otilonium Bromide chewable tablet, concrete formula is as follows:
Above-mentioned formula is made 1000 Simethicone otilonium Bromide chewable tablet, preparation method comprises the steps:
A. solids fraction in formula (otilonium Bromide, microcrystalline Cellulose, pregelatinized Starch, sucrose, glucose, magnesium stearate, saccharin sodium) is ground into the fine powder that fineness is more than 80 orders respectively;
B. the Simethicone getting formula ratio is mixed homogeneously with microcrystalline Cellulose; Mix homogeneously with the otilonium Bromide of formula ratio, pregelatinized Starch, sucrose, glucose, saccharin sodium again; Add 10% starch slurry and make soft material, cross 20 mesh sieves and granulate, 60 DEG C of dryings, then cross 20 mesh sieve granulate;
C. the essence of formula ratio is evenly sprayed on the dry particle surface of step b granulate, seals a moment, then add the magnesium stearate of formula ratio with sealing bag, mixing, tabletting, obtains Simethicone otilonium Bromide chewable tablet label;
D. moisture-proof film coating materials methylcellulose dissolve with ethanol is made the solution that mass fraction is 13%, then coating is carried out to Simethicone otilonium Bromide chewable tablet label, dry, i.e. obtained Simethicone otilonium Bromide chewable tablet.
Quality examination: Simethicone otilonium Bromide chewable tablet any surface finish, uniform color that the present embodiment is obtained; Good mouthfeel, savory; Hardness is 6.0-7.9kg; Dissolution test: when 30 minutes, the dissolution of Simethicone is 78.5%, and the dissolution of otilonium Bromide is 80.3%.
In above-described embodiment, adsorbent, except can using corn starch, microcrystalline Cellulose and calcium hydrogen phosphate, can also use dextrin; Filler, except using corn starch, sucrose, microcrystalline Cellulose, pregelatinized Starch, glucose and mannitol, can also use lactose, xylitol, maltose alcohol; Lubricant, except using magnesium stearate and micropowder silica gel, can also use Pulvis Talci; Binding agent, except using PVP-K30 and starch slurry, can also use low substituted hydroxy-propyl fiber; Correctives, except using aspartame and saccharin sodium, can also use steviosin and vanillin.
What finally illustrate is, above preferred embodiment is only in order to illustrate technical scheme of the present invention and unrestricted, although by above preferred embodiment to invention has been detailed description, but those skilled in the art are to be understood that, various change can be made to it in the form and details, and not depart from claims of the present invention limited range.
Claims (9)
1. Simethicone otilonium Bromide chewable tablet, it is characterized in that, composed of the following components by mass parts: Simethicone 12.5 parts, otilonium Bromide 4 parts, adsorbent 10-40 part, filler 25-75 part, adhesive 0.2-10 part, lubricant 0.2-5.0 part, correctives 0.5-10 part, aromatic 0.05-0.5 part and damp-proof membrane coating materials 1.5-7.5 part.
2. Simethicone otilonium Bromide chewable tablet according to claim 1, it is characterized in that, composed of the following components by mass parts: Simethicone 12.5 parts, otilonium Bromide 4 parts, adsorbent 16-32 part, filler 42-57.64 part, adhesive 2-2.6 part, lubricant 0.5-0.6 part, correctives 5.2-5.5 part, aromatic 0.14-0.15 part and damp-proof membrane coating materials 3.3-3.6 part.
3. Simethicone otilonium Bromide chewable tablet according to claim 1, is characterized in that: described adsorbent is one or more in corn starch, microcrystalline Cellulose, dextrin, calcium hydrogen phosphate.
4. Simethicone otilonium Bromide chewable tablet according to claim 1, is characterized in that: described filler is one or more in corn starch, sucrose, microcrystalline Cellulose, pregelatinized Starch, glucose, lactose, mannitol, xylitol, maltose alcohol.
5. Simethicone otilonium Bromide chewable tablet according to claim 1, is characterized in that: described lubricant is one or more in magnesium stearate, Pulvis Talci, micropowder silica gel.
6. Simethicone otilonium Bromide chewable tablet according to claim 1, is characterized in that: described adhesive is one or more in PVP-K30, starch slurry, low substituted hydroxy-propyl fiber.
7. Simethicone otilonium Bromide chewable tablet according to claim 1, is characterized in that: described correctives is one or more in aspartame, steviosin, saccharin sodium, vanillin.
8. Simethicone otilonium Bromide chewable tablet according to claim 1, is characterized in that: described damp-proof membrane coating materials is the one in hydroxypropyl emthylcellulose, methylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose.
9. the preparation method of Simethicone otilonium Bromide chewable tablet described in any one of claim 1 ~ 8, is characterized in that, comprise the following steps:
A. pulverize: the solids fraction in prescription is ground into the fine powder that granularity is more than 80 orders respectively;
B. granulate: the Simethicone getting formula ratio is mixed homogeneously with adsorbent, add filler, otilonium Bromide and correctives mix homogeneously again, add adhesive after mixing and make soft material, soft material is crossed 20 mesh sieves and granulate, then dry at 40 ~ 60 DEG C, finally cross 20 mesh sieve granulate;
C. tabletting: aromatic is evenly sprayed into mix homogeneously in the dry granule of step b granulate, then add the lubricant of recipe quantity, mixing, tabletting, obtains Simethicone otilonium Bromide chewable tablet label;
D. coating: moisture-proof film coating materials dissolve with ethanol is made the solution that mass fraction is 6-18%, carries out coating to step c gained Simethicone otilonium Bromide chewable tablet label, dry, i.e. obtained Simethicone otilonium Bromide chewable tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510004527.6A CN104523717A (en) | 2015-01-06 | 2015-01-06 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510004527.6A CN104523717A (en) | 2015-01-06 | 2015-01-06 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104523717A true CN104523717A (en) | 2015-04-22 |
Family
ID=52839474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510004527.6A Pending CN104523717A (en) | 2015-01-06 | 2015-01-06 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104523717A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173076A1 (en) * | 2015-05-14 | 2017-05-31 | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. | A pharmaceutical composition comprising simethicone and otilonium |
| WO2022060310A1 (en) * | 2020-09-18 | 2022-03-24 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising calcium carbonate, magnesium carbonat and simethicone |
| CN117323303A (en) * | 2023-10-09 | 2024-01-02 | 晋城海斯制药有限公司 | Preparation process of octreotide ammonium bromide tablet |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076478A1 (en) * | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| WO2010092436A1 (en) * | 2009-02-12 | 2010-08-19 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of simethicone and otilonium |
| CN102018721A (en) * | 2009-09-23 | 2011-04-20 | 黄石李时珍药业集团武汉李时珍药业有限公司 | Chewable tablet of calcium carbonate dimeticone and preparation process |
-
2015
- 2015-01-06 CN CN201510004527.6A patent/CN104523717A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076478A1 (en) * | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| WO2010092436A1 (en) * | 2009-02-12 | 2010-08-19 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical combinations of simethicone and otilonium |
| CN102018721A (en) * | 2009-09-23 | 2011-04-20 | 黄石李时珍药业集团武汉李时珍药业有限公司 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Non-Patent Citations (3)
| Title |
|---|
| 吕作培等: "结肠镜检查术前应用奥替溴铵的效果观察", 《浙江实用医学》 * |
| 周志宏等: "奥替溴铵治疗肠易激综合征的疗效观察", 《胃肠病学》 * |
| 张宏博等: "奥替溴铵、比特诺尔和复方地芬诺酯治疗肠易激综合征的双盲随机对照研究", 《中国临床药理学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3173076A1 (en) * | 2015-05-14 | 2017-05-31 | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. | A pharmaceutical composition comprising simethicone and otilonium |
| WO2022060310A1 (en) * | 2020-09-18 | 2022-03-24 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising calcium carbonate, magnesium carbonat and simethicone |
| CN117323303A (en) * | 2023-10-09 | 2024-01-02 | 晋城海斯制药有限公司 | Preparation process of octreotide ammonium bromide tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1911211B (en) | Solid oral preparation of leishajilan | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| CN102429887B (en) | Sodium-potassium citrate chewing tablet and preparation method thereof | |
| CN101658505A (en) | Sustained-release preparation of uloric and preparation method thereof | |
| CN105496977A (en) | Succinic acid trelagliptin orally-disintegrating tablets and preparing method thereof | |
| CN102488681B (en) | Ibuprofen diphenhydramine orally disintegrating tablet and preparation method thereof | |
| CN104523717A (en) | Simethicone otilonium bromide chewable tablets and preparing method thereof | |
| CN103656654A (en) | Instant orally-disintegrating tablet and its preparation method | |
| JP2006076971A (en) | Orally disintegrating tablet | |
| CN106074429A (en) | A kind of Vonoprazan fumarate effervescent tablet and preparation method thereof | |
| CN103054820B (en) | A kind of Dronedarone hydrochloride pharmaceutical composition and preparation method thereof | |
| ES2248850T3 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING SALTS OF POTASIOM SODIUM AND TRIS OF OXAPROZIN. | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN102038654A (en) | Cetirizine hydrochloride orally disintegrating tablets and preparation method thereof | |
| JP2010202579A (en) | Acarbose-containing disintegrating preparation in oral cavity | |
| CN101690720A (en) | Carteolol orally disintegrating tablets and preparation method thereof | |
| CN102727455A (en) | Tadalafil oral disintegrating tablet and preparation method thereof | |
| CN101982174A (en) | Formula of compound medicine preparation for relieving cough and preventing asthma and preparation method thereof | |
| CN100417392C (en) | An effervescence tablet of cold-treating preparation and preparation method thereof | |
| CN102440971A (en) | Iloperidone orally disintegrating tablet | |
| CN102488680B (en) | Ibuprofen diphenhydramine dispersing tablet and preparation method thereof | |
| CN100471497C (en) | Naloxone Hydrochloride nose powder preparation | |
| CN101797235B (en) | Carbazochrome sodium sulfonate oral disintegrating tablets and preparation method thereof | |
| JP2023504409A (en) | Tandospirone pharmaceutical composition and its production method and use | |
| CN100435804C (en) | Oral preparation of quick releasing stavudine, and producing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150422 |
|
| RJ01 | Rejection of invention patent application after publication |